Welcome to our dedicated page for Arbutus Biopharm SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma (NASDAQ:ABUS) announced the termination of its technology transfer and license agreement with Qilu Pharmaceutical Co., Ltd. The agreement, originally established in December 2021, granted Qilu exclusive rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan.
The mutual termination, effective June 20, 2025, involves no financial payments and results in all rights for imdusiran in Greater China and Taiwan reverting to Arbutus. This decision aligns with Qilu's pipeline reprioritization and Arbutus's strategic focus on efficient pipeline advancement.